Immunotherapy plus chemo may turn inoperable esophageal cancer into surgical candidates
NCT ID NCT07039162
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy can shrink advanced esophageal tumors enough to allow surgery. About 45 people with unresectable esophageal squamous cell carcinoma will receive the combination, followed by possible surgery. The main goal is to see if this approach improves 2-year survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) combined with chemotherapy (paclitaxel and cisplatin) and radiation
What this could lead to
If successful, this approach could help shrink advanced esophageal tumors enough to allow surgical removal, potentially improving long-term survival.
What could go wrong
This is an early Phase 2 trial with only 45 participants, so results may not apply broadly. The combination therapy carries risks of serious side effects from chemotherapy, radiation, and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, 404, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaohsiung Chang Gung Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linkou Chang Gung Memorial Hospital
NOT_YET_RECRUITINGTaoyuan, 33305, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
NOT_YET_RECRUITINGTaipei, 100225, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taichung Veterans General Hospital
NOT_YET_RECRUITINGTaichung, 407219, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••